The yeast Kodamaea ohmeri rarely causes life-threatening human infections. However, risk factors, laboratory diagnoses, and treatments for K. ohmeri infection have been limited, and the optimal therapy for K. ohmeri infection has not been identified. METHODS: Twenty cases of K. ohmeri infection have been reported in the English medical literature. We present two new cases of K. ohmeri fungemia. We investigated the nature and treatment of K. ohmeri infections using minimum inhibitory concentrations of antifungal agents and by comparing the two cases with those described in the literature. RESULTS: From March 1998 to December 2008, a total of 22 patients with K. ohmeri infections were studied. Hematological malignancies and diabetes were the most common co-morbidities for K. ohmeri infections, with crude prevalence rates of 27.3% and 18.2%, respectively. The K. ohmeri isolates showed less susceptibility to fluconazole but greater susceptibility to amphotericin B [15/25 isolates (60%) vs. 25/25 isolates (100%), respectively]. Good outcomes (8/9 cases; 88.9%) were found following removal of indwelling catheters and implants. In addition, voriconazole and echinocandins, such as caspofungin and micafungin, also showed excellent minimum inhibitory concentrations against K. ohmeri. CONCLUSION: K. ohmeri should not be regarded as a contaminant of blood cultures. Favorable outcomes for this potentially life-threatening infection are promoted by the removal of indwelling catheters; furthermore, outcomes are associated with optimal antifungal regimens, especially voriconazole and echinocandins.
Introduction
Fungi are being increasingly recognized as major pathogens in critically ill patients. Candida spp., Aspergillus spp., and Cryptococcus spp. comprise the majority of isolates in invasive fungal infections. 1, 2 Other yeasts and filamentous fungi, such as Blastomyces dermatitidis, dematiaceous fungi, Coccidioides spp., Fusarium spp., Histoplasma capsulatum, Scedosporium spp., Trichosporon spp., Penicillium spp., and Zygomycetes are emerging as significant human pathogens. 2, 3 Over the past decades, Kodamaea ohmeri has been recognized as an opportunistic pathogen, especially in immunocompromised patients. 4 This fungus has been rarely reported in the medical literature published since 1970. This report presents two new patients with a K. ohmeri infection that occurred within the same hospital service, and a review of previously reported cases.
Methods
We conducted a search (using the MEDLINE database) of the English medical literature from January 1970 to December 2008 using the following keywords: Pichia, Kodamaea ohmeri, and yeast. We found 20 reported cases of K. ohmeri infection. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Here, we report two new cases of K. ohmeri fungemia, one with concomitant cellulitis.
Case 1
A 71-year-old man was admitted to our hospital with fever, disturbance of consciousness, and cellulitis in his right leg. He had type 2 diabetes, coronary artery disease, iatrogenic Cushing's syndrome, major depression, and postsurgical herniation of an intervertebral disc in the lumbar spine. On admission, his body temperature was 39.3ºC, heart rate was 84 beats/min; respiratory rate was 24 breaths/ min, and blood pressure was 130/80 mmHg. Physical examination revealed erythema and swelling of his right leg. A complete blood cell count showed a white cell count of 7 × 10 9 /L with 74.9% neutrophils, and a C-reactive protein level of 78 mg/L. Blood biochemistry showed glucose was 14.4 mmol/L, triglycerides 8.1 mmol/L, and uric acid 487.7 umol/L. All other parameters were normal. The findings of urine analysis, chest radiograph, and an electrocardiogram were normal. The patient was empirically administered intravenous oxacillin for the treatment of his cellulitis. A yeast-like organism was isolated from the patient's blood, and he was given intravenous fluconazole (400 mg/day). Transthoracic echocardiography showed no evidence of vegetation of the cardiac valves. The yeast was identified as K. ohmeri. The patient remained febrile despite fluconazole therapy; therefore, the antifungal regimen was changed to amphotericin B deoxycholate (0.5 mg/ kg/day). Two weeks after this new treatment, the cellulitis in his right leg improved and subsequent blood cultures were negative.
Case 2
A 58-year-old woman was admitted to our hospital with dysphagia and a weight loss of 10 kg in the previous 3 weeks. 
Mycological studies
Blood cultures from the two cases were performed using the BacT/ALERT Microbial Detection System (bioMèrieux SA, Marcy-l'Etoile, France). The isolates from the cases were identified in our laboratory via morphological (SabouraudDextrose agar, Corn Meal agar, and CHROMagar) and biochemical methods (Vitek 2 YST, bioMèrieux, Hazelwood, Mo, USA). The susceptibility to antifungal agents was tested using the ATB Fungus 3 system (bioMèrieux SA, Marcyl'Etoile, France) according to the manufacturer's instructions. In 2007, the Clinical and Laboratory Standards Institute [CLSI; formerly the National Committee for Clinical Laboratory Standards (NCCLS)] published an approved reference method for broth microdilution testing (CLSI document M27-A3) of yeasts. 17 This method was developed through a consensus process to facilitate agreement among laboratories in determining the susceptibility of yeasts to several antifungal agents. The acceptable percent essential agreement for minimum inhibitory concentrations (MICs) was set at ≥ 90% for each antifungal agent against all organisms tested. Reference MICs were determined after 48 hours of incubation. The breakpoints in the antifungal susceptibility testing of yeasts, as defined by the CLSI, showed MICs of ≤ 1, ≤ 8, ≤ 0.125, ≤ 1, ≤ 2, ≤ 2 and ≤ 4 mg/L, to amphotericin B, fluconazole, itraconazole, voriconazole, caspofungin, micafungin, and flucytosine, respectively.
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Results
From March 1998 to December 2008, a total of 22 patients with K. ohmeri infections, including the present cases, were enrolled in this study. The yeast morphotype in the present cases showed white-rough colonies on Sabouraud-Dextrose agar plates, and underwent a change from pink to blue on CHROMagar plates (Figure) . The demographic data and clinical characteristics of patients with K. ohmeri infection are listed in Table 1 .
Sixteen males and six females (i.e. male-to-female ratio of ~3 :1) were enrolled. The ages ranged from a newborn baby to 84 years, with the mean age being 42 years. Infections included fungemia (19 cases, with 1 cellulitis, 1 phlebitis, 2 endocarditis, and 4 catheter infection cases; and 3 cases involving children), polymicrobial wound infection (1 case), urinary tract infection (1 case) and peritonitis (1 case). Hematological malignancy and diabetes were the two most common co-morbidities (27.3% and 18.2%, respectively). Other reported predisposing factors included neutropenia (4 cases), malignant solid tumors (3 cases), infant (3 cases), renal failure (2 cases), organ transplantation (1 case), hemochromatosis (1 case), and intravenous drug use (1 case). The presence of indwelling catheters or implants was an important risk factor associated with K. ohmeri infection, and removal of these catheters and implants was critical for successful management (8/9 cases; 88.9%).
The MICs of the antifungal agents used to treat the K. ohmeri strains isolated from the enrolled cases are shown in Table 2 [6] . AmB = Amphotericin B; Casp = caspofungin; FC = flucytosine; Flu = fluconazole; Itra = itraconazole; Mica = micafungin; Sus = reported as "susceptibility" only; Vori = voriconazole.
MICs of ≤ 0.50 (16/16; 100%), ≤ 0.25 (13/13; 100%), and ≤ 0.06 (13/13; 100%) mg/L to voriconazole, caspofungin, and micafungin, respectively. These are excellent MICs in comparison to the reference standards.
Discussion
The epidemiology of yeast infections has undergone significant changes over the last several decades, 2 and the annual incidence of fungemia has increased since the 1980s. The yeast K. ohmeri, previously known as Pichia ohmeri or Yamadazyma ohmeri, belongs to the Saccharomycetaceae family. 18 The first documented case was in an immunocompromised patient with K. ohmeri fungemia, reported in March 1998. 4 It was first classified as Endomycopsis ohmeri 19 and later transferred to the genus Pichia by Hansen.
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K. ohmeri has been placed in the guilliermondii-fibuligera group. 21 The epidemiology of invasive fungal infections in humans has changed significantly in the past decade. This is probably due to the use of broad-spectrum antibiotic therapy and antifungal prophylaxis, especially in hematologic patients.
1 K. ohmeri is an emerging opportunistic pathogen in clinical practice, and it should not be regarded as a contaminant of blood cultures. Although the most common risk factors for fungal infection have mainly been described in immunocompromised patients, 3 there is limited data on the risk factors, laboratory analysis, treatment, and prevention of K. ohmeri infection. From our review, K. ohmeri infections mainly occur in immunocompromised patients, [4] [5] [6] [7] [8] [9] [10] [12] [13] 15, 16 and less frequently in immunocompetent patients. 6, 11 In addition, indwelling catheters and implants are important risk factors associated with K. ohmeri infections. [4] [5] [6] [7] 9, 10, [12] [13] [14] [15] [16] Most yeasts are identified on the basis of carbohydrate assimilation and/or fermentation, and their macroscopic and microscopic morphological features after growth on specialized media. Two assays for yeast identification are the commercially available Vitek and API 20C assays. Although the API 20C assay is considered to be the gold standard for identification of K. ohmeri and other yeast species, a high false-positive rate with regard to K. ohmeri has been reported. 6 CHROMagar Candida chromogenic growth medium is an extremely useful tool for the identification of K. ohmeri and Candida species. This assay is based on the growth of colored colonies. 6 On a CHROMagar plate, K. ohmeri colonies undergo a characteristic change from pink to blue. 6, 9, 12 This unique characteristic is a simple and useful tool for the detection of K. ohmeri. Because of the poor prognosis for patients with invasive fungal infections, optimal treatments and/or antifungal strategies are important. Antifungal treatments include fluconazole, amphotericin B, or flucytosine, and these treatments can be combined with catheter removal, valve replacement, and surgical debridement ( Table 1) . Various antifungal regimens have been used to treat K. ohmeri infections, but fluconazole therapy has often been associated with poor responses and poor outcomes. [4] [5] [6] 9, 10, 13, 14, 16 While the optimal treatment for K. ohmeri infections are yet to be determined, our review shows good outcomes after removal of the indwelling catheters, pacemakers, and vegetated cardiac valves. [5] [6] [7] 10, 13, 14, 16 Furthermore, K. ohmeri seems to be resistant to fluconazole but is susceptible to amphotericin B. 22 In addition to these antifungal agents, the expanded-spectrum antimicrobials triazole, voriconazole, and the echinocandins, caspofungin and micafungin, have shown excellent MICs against K. ohmeri in previous reports and in our patients (Table 2) ; however, clinical experience with these agents in this setting is lacking.
In conclusion, K. ohmeri can cause life-threatening infections. Favorable outcomes for this potentially lifethreatening fungal infection are likely to be associated with early diagnosis, optimal antifungal regimens, and the removal of indwelling catheters. It should be pointed out that fluconazole is the least effective against K. ohmeri infections. Although further study is needed to establish the optimal antifungal regimens, voriconazole and echinocandins are suggested in treating K. ohmeri infections.
